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Abstract. Nesfatin is a peptide secreted by peripheral tissues, central and peripheral nervous sys-
tem. It is involved in the regulation of homeostasis. Although the eﬀects of nesfatin-1 on nutrition
have been studied widely in the literature, the mechanisms of nesfatin-1 action and also relations 
with other physiological parameters are still not clariﬁed well. We aimed to investigate the eﬀect
of peripheral chronic nesfatin-1 application on blood pressure regulation in normal and in rats 
exposed to restraint immobilization stress. In our study, three month-old male Wistar rats were 
used. Rats were divided into 4 groups as Control, Stress, Control+Nesfatin-1, Nesfatin-1+Stress. 
Angiotensinogen, angiotensin converting enzyme 2, angiotensin II, endothelin-1, endothelial nitric 
oxide synthase, aldosterone, cortisol, nesfatin-1 levels were determined in plasma samples by ELISA. 
Our results have shown that chronic peripheral nesfatin-1 administration increases blood pressure 
in normal and in rats exposed to chronic restraint stress. Eﬀect of nesfatin-1 on circulating level
of angiotensinogen, angiotensin converting enzyme 2, angiotensin II, endothelin-1, endothelial 
nitric oxide synthase, aldosterone and cortisol has been identiﬁed. We can conclude that elevated
high blood pressure after chronic peripheral nesfatin-1 administration in rats exposed to chronic
restraint stress may be related to decreased plasma level of endothelial nitric oxide synthase con-
centration.
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Introduction
Hypertension is very important worldwide public health 
challenge because of its high frequency and concomitant 
risks of cardiovascular disease. It has been identiﬁed as
a leading risk factor for mortality. The high prevalence
of hypertension worldwide has contributed to the present 
pandemic of stroke and cardiovascular diseases. The rapid
rise in the mortality of cardiovascular diseases is attribut-
able mainly to changes in environmental risk factors, such 
as diet and physical activity (Kearney et al. 2005; Agyemang 
et al. 2007).
Stressor can be broadly deﬁned as an actual or anticipated
disruption of homeostasis or an anticipated threat to well-
being. The survival and well-being of all species requires
appropriate physiological responses to environmental and 
homeostatic challenges. The re-establishment and mainte-
nance of homeostasis entails the coordinated activation and 
control of neuroendocrine and autonomic stress systems. 
The brain is the key organ for response to stress. That’s
why stressor-related information from all major sensory 
systems is conveyed to brain. Stress involves two-way com-
munication between brain and cardiovascular, immune, 
and other systems via neural and endocrine mechanisms. 
Brain activates neural and endocrine systems to minimize 
the harmful eﬀects of stress (McEwen 2007; Ulrich-Lai and
Herman 2009). Acute and chronic stresses increase the 
cardiovascular responses. Thereby, stress contributes to the
82 Ayada et al.
development of risk for hypertension and cardiovascular 
diseases, although the evidence is still inconclusive. It is 
generally accepted that stress-induced hypertension is due 
to the sequential increases in sympathoadrenal activity, 
norepinephrine and epinephrine release, and enhanced 
vascular tone; however, the long-lasting vasoconstriction 
induced by sympathetic nerve stimulation cannot be pre-
vented by complete α-adrenoreceptor blockade, suggesting 
that sympathetic nerve-mediated vasoconstriction may also 
be mediated by factors other than catecholamines (Han et 
al. 1998; Barbieri et al. 2012). 
Nesfatin-1 is an 82-amino-terminal fragment derived 
from the larger protein nucleobindin-2 (NUCB2) and is 
distributed in the central nervous system (CNS), implicated 
in the regulation of feeding, including the hypothalamic par-
aventricular nucleus (PVN), arcuate nucleus (ARC), lateral 
hypothalamic area and supraoptic nucleus (SON) (Oh-I et 
al. 2006). NUCB2 gene expression is signiﬁcantly regulated
by nutritional status, suggesting the role of nesfatin-1 in 
energy homeostasis (Stengel and Taché 2010). Nesfatin-1 
is localized in neurons of the hypothalamus and brain stem 
and colocalized with stress-related substances, corticotropin-
releasing hormone (CRH), oxytocin, proopiomelanocortin, 
noradrenaline (NA) and 5-hydroxytryptamine (5-HT). 
Intracerebroventricular (icv) administration of nesfatin-1 
produces fear-related behaviors and potentiates stressor-
induced increase in plasma adrenocorticotropic hormone 
(ACTH) and corticosterone levels in rats. It has been also 
shown that brain nesfatin-1 level is increased under stress 
conditions. These ﬁndings suggest that there should be
possible cross-talks between nesfatin-1 and stress (Yoshida 
et al. 2010). Some other studies have indicated that central 
administration of nesfatin-1 increases blood pressure (BP) 
but the mechanism of action has not been clariﬁed yet
(Yosten and Samson 2009; Yamawaki et al. 2012). Nesfatin-1 
suppresses feeding independently from the leptin pathway, 
and increases insulin secretion by activation of L-type Ca2+ 
channels in pancreatic islet beta cells (Shimizu et al. 2009; 
Nakata et al. 2011). Because of these eﬀects of nesfatin-1, it
became a popular therapeutic target in diseases such as obes-
ity and diabetes mellitus that are considered as chronic stress 
factor for human body. That’s why we hypothesized that
possible hypertensive eﬀect of nesfatin-1 could lead serious
health problems during the possible treatment procedures 
for various diseases. Thus, in present study experimental
model have been preferred to be able to mimic human body 
in disease conditions. We have identiﬁed the eﬀect of chronic
peripheral nesfatin-1 application on BP regulation in normal 
and in rats exposed to chronic immobilization stress. Plasma 
level of angiotensinogen (AGT), angiotensin converting 
enzyme 2 (ACE2), angiotensin II (AngII), endothelin-1, 
endothelial nitric oxide synthase (eNOS), aldosterone, 
cortisol and nesfatin-1 which are components involved in 
regulation of BP were measured. We aimed to identify pos-
sible relationship between nesfatin-1, stress condition, BP 
and related eﬀectors of BP.
Materials and Methods
Animals and experimental conditions
All experimental protocols conducted on animals were 
consistent with the National Institutes of Health Guidelines 
for the Care and Use of Laboratory Animals (NIH Publica-
tion No. 85-23) and approved by the Pamukkale University 
Ethics Committee of Animal Care and Usage. In this study 
three-months-old 28 male Wistar Albino rats weighing 
298–397 g were used. They were reared under the supervi-
sion of a veterinarian, kept in a well-ventilated, noiseless 
environment, and allowed free access to food and water. The
rats were housed in a room with controlled temperature (23 
± 1°C) and relative humidity (50 ± 5%), and they were kept in 
transparent plastic cages (42 × 26 × 15 cm), each containing 
three or four rats, exposed to a 12:12 light/dark cycle.
Experimental design 
The rats were randomly divided into four experimental
groups (n = 7). The groups were described as; control (C)
rats without any treatment, chronic restraint stressed (S) 
rats were placed in a specially built size-manipulable cabin 
for 2 h/day (between 10:00–12:00 A.M.) for 10 consecutive 
days without allowing water and food intake to be able to 
create the animal model of restraint stress (Vyas et al. 2002; 
Bhatia et al. 2011) without any injection, control+nesfatin-1 
applied (C+N) rats were treated with rat nesfatin-1 seg-
ment (0.25 nmol/g body weight i.p. injection) during the 10 
consecutive days (Shimizu et al. 2009), nesfatin-1 applied + 
chronic restraint stressed (N+S) rats were ﬁrst treated with
rat nesfatin-1 segment as in C+N group and after placed in
a specially built size-manipulable cabin as in S group. Totally 
for 14 rats in the C+N and N+S groups were treated with rat 
nesfatin-1 segment. Body weight of each rat was measured 
before and after all experimental process.
Blood pressure measurement
Systolic BP of each rats was measured by a non-invasive tail 
cuﬀ BP measuring system (Power Lab/8SP data acquisition
system, ADInstruments Co., Caringbah, NSW, Australia) 
before and after all experimental process. All measurements
were performed without anesthesia at room temperature in 
a silent room. The physiological data were analyzed using
the LabChart 6.1 Pro software (AD Instruments Co.) (Erken
et al. 2013). 
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Blood samples and measurements
At the end of the experimental period, all animals were an-
esthetized with ketamin/xylazine HCl (75 mg/kg/10 mg/kg 
intraperitoneally). Blood samples were collected in tubes 
with EDTA. After centrifugation, plasma of each rat was
stored at –80ºC until ELISA analysis. Plasma concentrations 
of AGT (Cusabio Biotech, Cat No CSB-E08565r), ACE2 
(Cusabio Biotech, Cat No CSB-E14308r), AngII (Cusabio 
Biotech, Cat No CSB-E04494r), endothelin-1 (Cusabio Bio-
tech, Cat No CSB-E06979r), eNOS (Cusabio Biotech, Cat No 
CSB-E08323r), aldosterone (Cusabio Biotech, Cat No CSB-
E07025r), cortisol (Cusabio Biotech, Cat No CSB-E05112r) 
and nesfatin-1 (Phoenix Pharma., Cat No EK-003-22) were 
analyzed by rat ELISA assay kits. Chemiluminescence data 
were analyzed by an ELISA microplate reader (das, Digital 
and Analog Systems, Vimercate, MI, Italy).
Statistical analysis
Statistical analyses were performed by SPSS (Statistical 
Package for Social Sciences, Chicago, IL, USA) 16.0 package 
program. All data are given as mean  ± standard deviation 
(SD). Statistical signiﬁcances were performed by Wilcoxon,
Kruskal-Wallis and Mann-Whitney U tests. Pearson cor-
relation test was used to analyze the correlation between 
obtained parameters. Diﬀerences were considered signiﬁcant
at p  < 0.05. 
Results
Body weights and blood pressures
We have observed that there are statistically signiﬁcant de-
creases of body weight for S, C+N, N+S groups compared to 
their own control (p = 0.028, p = 0.018, p = 0.018, respective-
ly; Table 1). As we compare all groups one by one with each 
other we could identify signiﬁcant decreases of body weight
in N+S group compared to C group (p = 0.017). Among all 
groups statistically signiﬁcant diﬀerence of BP have been
observed (p = 0.001). BP for C+N group was elevated signiﬁ-
cantly after nesfatin-1 administration (p = 0.028) (Table 2). 
We could identify that there were signiﬁcant increases of BP
in C+N and N+S groups compared to C group and in C+N 
and N+S groups compared to S group (p = 0.001, p = 0.005, 
p = 0.005, p = 0.03, respectively). 
Plasma levels of AGT, ACE2, AngII, aldosterone, cortisol, 
endothelin-1, eNOS, nesfatin-1 
Statistically signiﬁcant diﬀerence has been observed for
plasma level of AGT among the C (266.3 ± 58.53 ng/ml), 
S (314.37 ± 54.52 ng/ml), C+N (225.66 ± 47.51 ng/ml) and 
N+S (212.15 ± 43.64 ng/ml) groups (p = 0.006). Compari-
sons of groups one by one with each other have indicated 
that plasma levels of AGT were signiﬁcantly decreased in
C+N and N+S groups compared to S group (p = 0.007, p = 
0.002, respectively; Figure 1). 
Table 2. The level of blood pressure of rats in Control (C), Stress
(S), Nesfatin (N) and Nesfatin+Stress (N+S) groups before and after
nesfatin-1 and stress application
Group
Blood pressure (mmHg)
p n
before after
C  121.37 ± 4.21  123.09 ± 4.16 0.237 7
S  127.92 ± 11.85  131.60 ± 10.31 0.310 7
C+N  128.14 ± 10.25  151.63 ± 10.2 0.028 7
N+S  128.17 ± 7.63  146.81 ± 12.70 0.080 7
Data are mean ± SD. p shows the diﬀerences between groups
(Wilcoxon Test).
Table 1. The level of body weight of rats in Control (C), Stress (S),
Nesfatin (N) and Nesfatin+Stress (N+S) groups before and after
nesfatin-1 and stress application 
Group
Body weight (g)
p n
before after
C  353.14 ± 34.94  353.71 ± 35.74 0.194 7
S  328.14 ± 11.96  317.42 ± 16.56 0.028 7
C+N  353.71 ± 35.74  328.85 ± 41.05 0.018 7
N+S  333.71 ± 12.48  309.71 ± 12.16 0.018 7
Data are mean ± SD. p shows the diﬀerences between groups
(Wilcoxon Test).
Figure 1. Plasma levels of AGT in Control (C), Stress (S), 
Control+Nesfatin-1 (C+N), Nesfatin-1+Stress (N+S) groups. **, ## p < 
0.01 vs. S group (Mann Whitney U test). AGT, angiotensinogen.
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For plasma level of ACE2 we could also identify statistically 
signiﬁcant diﬀerence among the C (3.36 ± 0.63 IU/ml), S (3.17
± 0.61 IU/ml), C+N (4.43 ± 1.23 IU/ml) and N+S (4.45 ± 1.30 
IU/ml) groups (p = 0.021). It has been observed that there were 
statistically signiﬁcant increases for plasma levels of ACE2 in
C+N and N+S groups compared to C group and in C+N and 
N+S groups compared to S group (p = 0.038, p = 0.038, p = 
0.038, p = 0.017, respectively; Figure 2). 
We could not observe any statistically signiﬁcant diﬀerence
for plasma level of AngII among the C (2.27 ± 0.52 pg/ml), 
S (3.32 ± 0.42 pg/ml), C+N (3.05 ± 0.87 pg/ml) and N+S (3.04 ± 
0.49 pg/ml) groups (p = 0.05). However, comparisons of groups 
one by one with each other have indicated that plasma levels 
of AngII were signiﬁcantly increased in S and N+S groups com-
pared to C group (p = 0.01, p = 0.03, respectively; Figure 3). 
Comparison of plasma level of eNOS among the C (42.41 
± 3.44 mIU/ml), S (52.29 ± 7.43 mIU/ml), C+N (41.14 ± 
15.61 mIU/ml) and N+S (29.65 ± 6.83 mIU/ml) group has 
given a statistically signiﬁcant diﬀerence (p = 0.004). It has 
been observed that plasma level of eNOS was signiﬁcantly
increased in S group compared to C group (p = 0.01), signiﬁ-
cantly decreased in N+S group compared to C and S groups 
(p = 0.009, p = 0.001, respectively; Figure 4).
We could not observe any statistically signiﬁcant diﬀer-
ence for plasma level of nesfatin-1 among the C (7.40 ± 1.63 
µg/ml), S (8.53 ± 1.71 µg/ml), C+N (9.26 ± 1.73 µg/ml) and 
N+S (9.45 ± 1.49 µg/ml) groups (p = 0.136). However, it 
has been identiﬁed that plasma level of nesfatin-1 in N+S
group was signiﬁcantly higher than C group (p = 0.026) 
(Figure 5). 
No statistically signiﬁcant diﬀerences have been found
for plasma levels of aldosterone, cortisol, and endothelin-1 
among all groups. Plasma level of nesfatin-1 was in positive 
correlation with plasma level of AGT, ACE2, AngII, eNOS 
Figure 2. Plasma levels of ACE2 in C, S, C+N, N+S groups. * p < 
0.05 vs. C group (Mann Whitney U test). # p < 0.05 vs. S group 
(Mann Whitney U test). ACE2, angiotensin converting enzyme 2. 
For more abbreviations see Fig. 1.
Figure 3. Plasma levels of AngII in C, S, C+N, N+S groups. *, # p < 
0.05 vs.C group (Mann Whitney U test). AngII, angiotensin II. For 
more abbreviations see Fig. 1.
and endothelin-1 and in negative correlation with plasma 
level of aldosterone and cortisol, although not statistically 
signiﬁcant (data did not shown).
Discussion
Hypertension is a multifactorial and important health 
problem caused by genetic and environmental factors 
(Stengel and Taché 2010). Cardiovascular responses oc-
cur after acute and chronic stress, which can increase the
risk of hypertension and cardiovascular diseases (Bechtold 
et al. 2009). Nesfatin-1 can control appetite in a diﬀerent
pathway than leptin and increases insulin secretion by 
activation of L-type Ca2+ channels in pancreatic islet beta 
cells (Cowley and Grove 2006; Nakata et al. 2011). Because 
of these eﬀects of nesfatin-1, it became a popular therapeutic
target. It has been also reported that nesfatin-1 elevates BP 
(Yosten and Samson 2009; Yamawaki et al. 2012). We sup-
pose that improving our knowledge about nesfatin-1 can 
help to eliminate its controversial eﬀects during treatment
processes. In literature, the eﬀects of nesfatin-1 on appetite
have been studied on a large scale, but still we need to know 
more clues about its physiological eﬀects and the mecha-
nisms of these eﬀects.
In this present study, we have tried to identify the eﬀect
of chronic peripheral nesfatin-1 application on BP regulation 
in normal and in rats exposed to chronic immobilization 
stress. We have also aimed to indicate the possible relation-
ship between nesfatin-1 and stress condition, BP and related 
eﬀectors of BP such as AGT, ACE2, AngII, endothelin-1,
eNOS, aldosterone and cortisol.
It has been reported that peripheral nesfatin-1 applica-
tion decreases body weight by inhibiting feeding (Oh-I et 
al. 2006; Shimizu et al. 2009). We have also observed that 
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chronic peripheral nesfatin-1 administration has caused 
signiﬁcantly loss of body weight. These results can be taken
as a marker about the eﬃcacy of nesfatin-1 application.
Chronic restraint stress can cause loss of body weight re-
lated with diet or feeding behavior (Harris et al. 1998, 2006; 
Hennebelle et al. 2012). In the present study, we have also 
observed a signiﬁcant decrease of body weight in the S group
after experimental process.
It has been identiﬁed by diﬀerent groups that acute stress
increases the central level of nesfatin-1 (Goebel et al. 2009; 
Xu et al. 2010). However, acute stress does not inﬂuence
plasma level of nesfatin-1 (Yoshida et al. 2010). Until now, 
we could not observe any study that examined the eﬀect
of chronic restraint stress on plasma level of nesfatin-1. 
According to our results, we could observe signiﬁcantly
elevated plasma level of nesfatin-1 in N+S group compared 
to C group. Unfortunately, according to our results, it is not 
certain whether this elevation is caused by stress or nesfatin-1 
administration, although plasma levels of nesfatin-1 were 
increased in S and C+N groups compared to C group, but 
not signiﬁcantly.
To this point, it has been indicated that chronic stress does 
not have an eﬀect on BP (Scheuer et al 2007; Bechtold et al.
2009; Scheuer 2010) and nesfatin-1 increases BP (Yosten 
and Samson 2009, 2010; García-Galiano et al. 2010). Yosten 
and his colleagues have showed that intracerebroventricular 
nesfatin-1 administration increases BP (Yosten and Samson 
2009) and this eﬀect of nesfatin-1 occurs via sympathetic 
system activation (Yosten and Samson 2010). Recently, it has 
been shown that intravenous nesfatin-1 administration can 
also increase BP by inhibiting nitric oxide (NO) production 
(Yamawaki et al. 2012). According to our results, we suggest 
that chronic peripheral nesfatin-1 application can elevate BP 
in normal and chronic restraint stressed rats. 
Nesfatin-1 is a rather new subject in research. It should 
be the reason that there is not any report about its eﬀect
on circulating level of AGT, AngII, ACE2, endothelin-1, 
aldosterone, cortisol and eNOS. Current study have indi-
cated that nesfatin-1 causes decreased plasma level of AGT 
and increased plasma level of ACE2 in both C+N and N+S 
groups. According to this result, we may conclude that nes-
fatin-1 have possible function in homeostasis in normal and 
stress conditions. We could observe a signiﬁcant increase
for the plasma level of AngII in N+S group compared to 
C group. On the other hand, it is not clear whether this 
increase is caused by nesfatin-1 application or not because 
we also observed an increased plasma level of AngII in 
S group compared to C group. That is why we did not obtain
a certain result about the eﬀect of nesfatin-1 on plasma level
of AngII. On the other hand, if we focus on decreased plasma 
level of AngII in N+S group compared to S group, although 
not statistically signiﬁcant, this decrease may be caused by
nesfatin-1 application, which causes also increased plasma 
level of ACE2, under chronic stress condition. Accord-
ing to the literature, the main substrate of ACE2 is AngII. 
Especially in the regulation of cardiovascular homeostasis 
the function of ACE2 is more important than the function 
of ACE because the levels of Ang II and Ang 1–7 are mainly 
regulated by ACE2 for balanced function of renin-angi-
otensin-aldosterone system (RAAS) (Tikellis and Thomas
2012). That is why we may conclude that decreased plasma
level of AngII is in correlation with increased plasma level 
of ACE2 in N+S group.
Acute and chronic stress applications can increase 
plasma levels of RAAS components (Cody 1997; Saavedra 
et al. 2004; Goebel et al. 2009; Groeschel and Braam 2011). 
On the other hand, we could not reach any information 
about the direct eﬀect of applied stress model on plasma
Figure 5. Plasma levels of nesfatin-1 in C, S, C+N, N+S groups. 
* p < 0.05 vs.C group (Mann Whitney U test). For more abbrevia-
tions see Fig. 1. 
Figure 4. Plasma levels of eNOS in C, S, C+N, N+S groups. * p < 
0.05 vs. C group; ## p < 0.01 vs.C group; †† p < 0.01 vs.S group 
(Mann Whitney U test). eNOS, endothelial nitric oxide synthase. 
For more abbreviations see Fig. 1.
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level of AGT and ACE2. In this present study, we have 
observed statistically signiﬁcant increase in plasma level
of AngII in S group compared to C group. Additionally, 
the increased plasma level of AGT and decreased plasma 
level of ACE2, although not statistically signiﬁcant, were
observed in S group compared to C group. These ﬁndings
are supplementary to each other. To clarify the eﬀects
of applied stress on plasma level of AGT and ACE2, further 
experiments are needed. 
It is very well known that stress response correlates with 
increased basal blood level of mineralocorticoids and glu-
cocorticoids (McEwen 2007; Ulrich-Lai and Herman 2009; 
Bechtold et al. 2009). On the other hand, desensitization 
to repeated stress exposure has been explained linked with 
recovery of plasma level of corticosterones and adrenocorti-
cotropic hormone (ACTH). Model and duration of applied 
stress can alter the stress response. At the same time, stress 
response observations can have diverseness with sampling 
time (Dal-Zotto et al. 2002, 2003). In the present study, we 
could not observe any signiﬁcant changes in plasma levels
of aldosterone, cortisol, and endothelin-1 in groups exposed 
to stress. We think these ﬁndings are related with the applied
stress model and our sampling time.
It has been reported that peripheral nesfatin-1 adminis-
tration does not have any eﬀect on stress response (Yoshida
et al. 2010). If we consider that stress response is related to 
plasma levels of aldosteron and cortisol, chronic periph-
eral nesfatin-1 administration does not have any eﬀect on
plasma levels of aldosterone and cortisol. Although the 
main glucocorticoid in rats is corticosterone, not cortisol 
as in human (Ulrich-Lai and Herman 2009), we measured 
plasma level of cortisol. Thus, we have to indicate that
this point of our results limits the understanding of the 
real relationship between the eﬀect of chronic peripheral
nesfatin-1 administration on BP and initiation of central 
stress response. If our results and literature are taken into 
account, we can conclude that the eﬀect of chronic pe-
ripheral nesfatin-1 on BP may not be related with initiated 
central stress response. 
In spite of increased BP by nesfatin-1 application, we 
could not observe statistically signiﬁcant diﬀerences in
plasma level of endothelin-1, aldosterone and cortisol in 
groups with elevated high BP. We have not assessed the 
eﬀects of high BP on these parameters due to limitation
of experimental design. Thus, we assume that another set
of experiment can clarify the eﬀects of high BP.
NO is known as an important vasodilator. It causes 
vasodilatation via inhibiting the eﬀects of vasoconstrictors
such as AngII and endothelin-1 (Rubbo et al. 2002; Davi-
gnon and Ganz 2004). NO is synthesized by a family of NO 
synthases (NOSs) isoforms that are neuronal, endothelial 
and inducible NOS (referred respectively; nNOS, eNOS 
and iNOS) (Kleinbongard et al. 2006). Although all iso-
forms of NOSs have regulatory function on cardiovascular 
system, eNOS has a special importance as a BP regulator 
via vasodilator eﬀect on blood vessels (Balligand et al.
2009). Circulating level of eNOS can be derived from 
vascular endothelium and red blood cells (RBCs) and has 
an importance in cardiovascular pathophysiology because 
of its contribution to the circulating NO pool; on the other 
hand, the origin of NO synthesis within the plasma (RBCs 
or non-RBCs) cannot be diﬀerentiated (Kleinbongard et 
al. 2006; Cortese-Krott and Kelm 2014). In this present 
study, we cannot explain the exact source of eNOS apart 
from the total amount of eNOS. We have observed that 
chronic restraint stress signiﬁcantly increases plasma level
of eNOS. Based on our knowledge, increased vascular 
endothelial growth factor (VEGF) causes increased tumor 
eNOS level in chronic-stressed mice (Barbieri et al. 2012). 
Additionally, RBCs can contribute NO bioavailability by 
releasing ATP under hypoxia and shear stress condition. 
Thereby, RBCs induce eNOS dependent vasorelaxation
and increase in blood ﬂow under stress-related conditions
(Cortese and Kelm 2014). Collectively, we can conclude 
that applied stress model can cause elevated plasma level 
of eNOS in rats.
Recently, it has been shown that intravenous nesfatin-1 
application increases vessel contraction via repressing NO 
production and subsequently causes high BP (Yamawaki 
et al. 2012). According to our results, it is highly possible 
that chronic peripheral nesfatin-1 decreases plasma level 
of eNOS speciﬁcally in rats subjected to chronic restraint
stress. Consistent with these observations, eNOS and NO 
may be the key factors for chronic peripheral nesfatin-1 
eﬀect on BP especially in stressed condition.
In conclusion, chronic peripheral nesfatin-1 adminis-
tration can cause high BP in normal and in rats subjected 
to chronic restraint stress. This eﬀect of nesfatin-1 is not
aﬀected by stimulated central stress response, elevated level
of AGT, AngII and decreased level of ACE2 under normal 
and stressed conditions. Additionally, the eﬀect of chronic
peripheral nesfatin-1 administration on BP can be related 
with decreased eNOS production especially in stressed con-
dition. Nesfatin-1 has a raising attention as a therapeutic 
agent for various diseases. We believe knowing more 
about the eﬀects of nesfatin-1 on diﬀerent physiological
parameters in diﬀerent conditions can provide beneﬁts for
the eﬀective usage of nesfatin-1 in therapeutic processes.
Thus, we suppose further experiments are necessary on
this subject.
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